Revolution Medicines' daraxonrasib phase III data showed a 60% reduction in death risk and a doubling of median survival in treated pancreatic cancer patients. The result is a major clinical efficacy signal for the company's lead asset and materially strengthens the drug's commercial and regulatory outlook. Shares jumped on the readout, with the news likely to be material for the stock and the biotech subsector.
Revolution Medicines' daraxonrasib phase III data showed a 60% reduction in death risk and a doubling of median survival in treated pancreatic cancer patients. The result is a major clinical efficacy signal for the company's lead asset and materially strengthens the drug's commercial and regulatory outlook. Shares jumped on the readout, with the news likely to be material for the stock and the biotech subsector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.82
